ArticleDiscover oncology2025
LncRNA MIR99AHG serves as a diagnostic marker for early lung cancer and regulates cancer cell growth and metastasis via miR-194-5p.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress on long non‑coding RNAs in lung cancer (Review).Molecular medicine reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer ranks among the foremost causes of mortality associated with cancer. Non-small cell lung cancer (NSCLC) represents the predominant subtype, and the survival rate is suboptimal.
objectivesThis study investigated the clinical relationship between MIR99AHG and NSCLC, as well as elucidated the potential mechanisms. This study identified novel molecular targets for NSCLC. PATIENTS AND
methodsThis study involved 119 NSCLC patients and 105 benign lung lesions patients. qPCR was employed to assess the expression of MIR99AHG and miR-194-5p. The clinical correlation, diagnostic value, and predictive capacity of MIR99AHG were evaluated utilizing chi-square tests, ROC analysis, and logistic regression models, respectively. A cell model exhibiting overexpression of MIR99AHG was established, and the impact of MIR99AHG overexpression, and in conjunction with miR-194-5p overexpression, on the functional characteristics of lung cancer cells was investigated through CCK-8 and Transwell assays.
resultsMIR99AHG exhibited down-regulation in NSCLC patients' serum and lung cancer cell lines, while miR-194-5p showed up-regulation. The expression of MIR99AHG was correlated with TNM staging and LNM status in early-stage NSCLC patients. MIR99AHG demonstrated predictive capabilities for the early NSCLC occurrence, both independently and in conjunction with serum tumor markers, and exhibited significant diagnostic potential for this condition. Moreover, the overexpression of MIR99AHG could inhibit the proliferation, migration, and invasion of lung cancer cells. However, the concurrent overexpression of MIR99AHG and miR-194-5p appeared to negate this inhibitory effect.
conclusionMIR99AHG might as a supplementary diagnosis tool for early NSCLC. Furthermore, MIR99AHG could regulate the initiation and advancement of NSCLC via miR-194-5p.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.